Ufuk ATLIHAN , Onur YAVUZ , Selcuk ERKILINC , Tevfik Berk BILDACI , Can ATA , Huseyin Aytug AVSAR
{"title":"EFFECT OF LEVONORGESTREL IUD USE ON DYSPAREUNIA AND FEMALE SEXUAL FUNCTIONS IN PATIENTS WITH ADENOMYOSIS","authors":"Ufuk ATLIHAN , Onur YAVUZ , Selcuk ERKILINC , Tevfik Berk BILDACI , Can ATA , Huseyin Aytug AVSAR","doi":"10.1016/j.rbmo.2024.104563","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study is to investigate the effects of levonorgestrel intrauterine device (LNG-IUD) use for contraception on dyspareunia and female sexual functions.</div></div><div><h3>Materials and Methods</h3><div>Our study included 96 women who applied to our gynecology outpatient clinic for routine check-ups and whose ultrasonographic findings were compatible with adenomyosis. Among these patients, LNG-IUD application was performed in 54 patients, and 42 patients did not accept the treatment. Among these patients, 54 patients underwent LNG-IUD application due to menometrorrhagia symptoms, and 42 patients did not accept the treatment. All patients were evaluated at a routine check-up 6 months after diagnosis, and all patients underwent Quality of Sexual Experience Scale (QSES), Female Sexual Function Index (FSFI), Visual Analog Scale (VAS) survey.</div></div><div><h3>Results</h3><div>No significant difference was detected between the average age and BMI averages of patients using LNG-IUD and patients not using LNG-IUD (p>0.05, p>0.05 respectively). There was no significant difference between the gravida and parity averages of patients using LNG-IUD and patients not using LNG-IUD (p>0.05, p>0.05 respectively). The VAS-dyspareunia score of patients using LNG-IUD was 3.88+0.64, and that of patients not using it was 4.36+0.72, and it was found to be significantly lower in the LNG group (p<0.026). The FSFI score of patients using LNG-IUD was 28.70+2.16, and that of patients not using it was 24.80+1.96, and it was found to be significantly higher in the LNG group (p<0.018). The QSES score of patients using LNG-IUD was 37.60+3.36, and that of patients not using it was 33.64+3.12, and it was found to be significantly higher in the LNG group (p<0.018).</div></div><div><h3>Conclusion</h3><div>We think that the use of LNG-IUD in the medical treatment of adenomyosis in the reproductive period will have a positive effect on female sexual functions, especially on dyspareunia.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"49 ","pages":"Article 104563"},"PeriodicalIF":3.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive biomedicine online","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1472648324007521","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
The aim of this study is to investigate the effects of levonorgestrel intrauterine device (LNG-IUD) use for contraception on dyspareunia and female sexual functions.
Materials and Methods
Our study included 96 women who applied to our gynecology outpatient clinic for routine check-ups and whose ultrasonographic findings were compatible with adenomyosis. Among these patients, LNG-IUD application was performed in 54 patients, and 42 patients did not accept the treatment. Among these patients, 54 patients underwent LNG-IUD application due to menometrorrhagia symptoms, and 42 patients did not accept the treatment. All patients were evaluated at a routine check-up 6 months after diagnosis, and all patients underwent Quality of Sexual Experience Scale (QSES), Female Sexual Function Index (FSFI), Visual Analog Scale (VAS) survey.
Results
No significant difference was detected between the average age and BMI averages of patients using LNG-IUD and patients not using LNG-IUD (p>0.05, p>0.05 respectively). There was no significant difference between the gravida and parity averages of patients using LNG-IUD and patients not using LNG-IUD (p>0.05, p>0.05 respectively). The VAS-dyspareunia score of patients using LNG-IUD was 3.88+0.64, and that of patients not using it was 4.36+0.72, and it was found to be significantly lower in the LNG group (p<0.026). The FSFI score of patients using LNG-IUD was 28.70+2.16, and that of patients not using it was 24.80+1.96, and it was found to be significantly higher in the LNG group (p<0.018). The QSES score of patients using LNG-IUD was 37.60+3.36, and that of patients not using it was 33.64+3.12, and it was found to be significantly higher in the LNG group (p<0.018).
Conclusion
We think that the use of LNG-IUD in the medical treatment of adenomyosis in the reproductive period will have a positive effect on female sexual functions, especially on dyspareunia.
期刊介绍:
Reproductive BioMedicine Online covers the formation, growth and differentiation of the human embryo. It is intended to bring to public attention new research on biological and clinical research on human reproduction and the human embryo including relevant studies on animals. It is published by a group of scientists and clinicians working in these fields of study. Its audience comprises researchers, clinicians, practitioners, academics and patients.
Context:
The period of human embryonic growth covered is between the formation of the primordial germ cells in the fetus until mid-pregnancy. High quality research on lower animals is included if it helps to clarify the human situation. Studies progressing to birth and later are published if they have a direct bearing on events in the earlier stages of pregnancy.